ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug…